公开(公告)号：US20200368259A1

公开(公告)日：2020-11-26

申请号：US16635769

申请日：2018-08-02

申请人： Indiana University Research and Technology Corporation ,  University of Rochester ,  The United States of America As Represented by the Department of Veterans Affairs Office of General

发明人： Teresita M. Bellido ,  G. David Roodman ,  Jesus Delgado-Calle ,  Robert K. Boeckman ,  Frank H. Ebetino

IPC分类号： A61K31/664 ,  C07F9/38 ,  A61K45/06 ,  A61K38/29 ,  A61P35/00

摘要： Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

公开(公告)号：US20200289622A1

公开(公告)日：2020-09-17

申请号：US16649325

申请日：2018-09-20

申请人： ASAHI KASEI PHARMA CORPORATION

发明人： Kohei MIYABE ,  Atsushi OSE ,  Yuki SATO ,  Toshiyuki KODAMA ,  Yasuhiro MATSUNAWA ,  Hikaru YAMAMOTO

IPC分类号： A61K38/29 ,  A61K9/00 ,  A61K9/08

摘要： A liquid pharmaceutical preparation for subcutaneous administration in human containing 28.2 μg of teriparatide or a salt thereof (Component 1) in a unit dose in terms of teriparatide, wherein the Component 1 concentration is from 80 to 240 μg/mL. This liquid pharmaceutical preparation is excellent in the viewpoint of pharmacokinetics.

公开(公告)号：US10683335B2

公开(公告)日：2020-06-16

申请号：US15991485

申请日：2018-05-29

申请人： ASAHI KASEI PHARMA CORPORATION

发明人： Fumihide Nishio ,  Takuji Maejima ,  Yoshiro Mitome

IPC分类号： A61K38/22 ,  A61K9/19 ,  C07K14/635 ,  F26B5/06 ,  G01N30/88 ,  G01N33/68 ,  A61K38/29 ,  B65B55/10 ,  B65B55/12 ,  B65B63/08 ,  G01N30/72

摘要： Provided herein are freeze-dried preparations comprising a high-purity parathyroid hormone (PTH) peptide and one or more PTH analogs, and methods for the production thereof. Also provided is a test method for detecting PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like.

公开(公告)号：US10603475B2

公开(公告)日：2020-03-31

申请号：US16275586

申请日：2019-02-14

申请人： Rani Therapeutics, LLC

发明人： Mir Imran

IPC分类号： A61M31/00 ,  A61K31/155 ,  A61K38/26 ,  A61K38/28 ,  A61K9/48 ,  A61M5/20 ,  A61K38/27 ,  A61M5/168 ,  A61K38/22 ,  A61K45/06 ,  A61K38/29 ,  A61K9/00 ,  A61K38/17 ,  A61M5/172 ,  A61M5/142 ,  A61M5/14

摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

公开(公告)号：US20200009045A1

公开(公告)日：2020-01-09

申请号：US16514967

申请日：2019-07-17

申请人： Rani Therapeutics, LLC

发明人： Mir Imran

IPC分类号： A61K9/00 ,  A61M25/10 ,  A61M5/00 ,  A61K38/29 ,  A61K9/48 ,  A61K31/155 ,  A61M31/00 ,  A61M37/00

摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

公开(公告)号：US20190381341A1

公开(公告)日：2019-12-19

申请号：US16482897

申请日：2018-02-01

申请人： THE JOHNS HOPKINS UNIVERSITY

发明人： Xu CAO

IPC分类号： A61P19/10 ,  A61P35/00 ,  A61K38/29

摘要： The present invention provides methods for treatment of IVD degeneration and/or LDD in a subject having symptoms of WD degeneration and/or LDD comprising administering to the subject an effective amount of Parathyroid hormone (PTH) or a functional fragment or analog thereof. Reduction in IVD degeneration and regeneration of IVD using the inventive methods is also provided.

公开(公告)号：US10478396B2

公开(公告)日：2019-11-19

申请号：US15879308

申请日：2018-01-24

申请人： Rani Therapeutics, LLC

发明人： Mir Imran

IPC分类号： A61K9/48 ,  A61K9/00 ,  A61M25/10 ,  A61M5/00 ,  A61K38/29 ,  A61K31/155 ,  A61M31/00 ,  A61M37/00

摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

公开(公告)号：US20190282668A1

公开(公告)日：2019-09-19

申请号：US16337955

申请日：2017-09-28

申请人： Ascendis Pharma Bone Diseases A/S

发明人： Kennett Sprogøe ,  Lars Holten-Andersen ,  David Brian Karpf

IPC分类号： A61K38/29 ,  A61K47/60

摘要： The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.

公开(公告)号：US20190135890A1

公开(公告)日：2019-05-09

申请号：US16249540

申请日：2019-01-16

申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS ,  OCHSNER CLINIC FOUNDATION ,  NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY

发明人： Robert C. Gensure ,  Joshua Sakon ,  Osamu Matsushita ,  Tulasi Ponnapakkam

IPC分类号： C07K14/635 ,  A61K9/00 ,  C12N9/10 ,  C12N9/64 ,  C12N9/50 ,  A61K35/28 ,  A61K38/16 ,  A61K8/64 ,  A61K8/66 ,  A61K38/48 ,  A61K38/29 ,  A61Q7/00 ,  C12N9/52

CPC分类号： C07K14/635 ,  A61K8/64 ,  A61K8/66 ,  A61K9/0019 ,  A61K35/28 ,  A61K38/164 ,  A61K38/29 ,  A61K38/4886 ,  A61K2800/86 ,  A61K2800/91 ,  A61Q7/00 ,  C07K2319/00 ,  C07K2319/50 ,  C07K2319/70 ,  C12N9/1088 ,  C12N9/50 ,  C12N9/52 ,  C12N9/6489 ,  C12Y205/01018 ,  C12Y304/24003 ,  C12Y304/24007

摘要： Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

公开(公告)号：US20190117739A1

公开(公告)日：2019-04-25

申请号：US16092587

申请日：2017-04-06

申请人： RADIUS HEALTH, INC.

发明人： Gary HATTERSLEY ,  Alan HARRIS ,  Jamal SAEH ,  Ehab HAMED

IPC分类号： A61K38/29 ,  A61K47/10 ,  A61K33/30 ,  A61K33/06 ,  A61K9/00 ,  A61P19/10 ,  A61P19/02

CPC分类号： A61K38/29 ,  A61K9/0014 ,  A61K9/0021 ,  A61K9/703 ,  A61K33/06 ,  A61K33/30 ,  A61K47/10 ,  A61P19/02 ,  A61P19/10

摘要： Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.